Zimberelimab
- Generic Name
- Zimberelimab
- Drug Type
- Biotech
- CAS Number
- 2259860-24-5
- Unique Ingredient Identifier
- ZBL7O904IL
- Indication
用于治疗二线以上复发或难治性经典型霍奇金淋巴瘤（r/r cHL）患者。
Study of GS-1811 Given Alone or With Zimberelimab in Adults With Advanced Solid Tumors
- First Posted Date
- 2021-08-16
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 376
- Registration Number
- NCT05007782
- Locations
- 🇺🇸
University of California San Diego, La Jolla, California, United States
🇺🇸Stanford Cancer Center, Palo Alto, California, United States
🇺🇸Smilow Cancer Center, New Haven, Connecticut, United States
AB122 Platform Study
- Conditions
- Advanced or Metastatic Solid TumorPancreatic Ductal AdenocarcinomaColorectal CancerNon-small Cell Lung CancerGastric CancerAlveolar Soft Part SarcomaEsophageal CancerHead and Neck CancerBiliary Tract Cancer
- Interventions
- First Posted Date
- 2021-08-11
- Last Posted Date
- 2024-02-16
- Lead Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Target Recruit Count
- 715
- Registration Number
- NCT04999761
- Locations
- 🇯🇵
A site selected by Taiho Pharmaceutical Co., Ltd., Wakayama, Japan
A Study of Concurrent Chemoradiation in Combination With or Without PD1 Inhibitor AB122 Adenosine 2a Receptor / Adenosine 2b Receptor Inhibitor AB928 Therapies in Locally Advanced Head and Neck Cancers
- Conditions
- Oral Cavity Squamous Cell CarcinomaSquamous Cell Carcinoma of Head and NeckHypopharynx Squamous Cell CarcinomaOral Cavity CancerOropharynx CancerPharynx CancerHead and Neck CancerOropharynx Squamous Cell CarcinomaLarynx CancerHypopharynx Cancer
- Interventions
- First Posted Date
- 2021-05-19
- Last Posted Date
- 2023-11-30
- Lead Sponsor
- Jennifer Choe
- Registration Number
- NCT04892875
Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma
- Conditions
- Head and Neck Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2021-04-22
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 193
- Registration Number
- NCT04854499
- Locations
- 🇺🇸
UCLA Hematology/Oncology, Los Angeles, California, United States
🇺🇸Memorial Healthcare System, Hollywood, Florida, United States
🇧🇪Algemeen Ziekenhuis Klina, Brasschaat, Belgium
Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung Cancer
- Conditions
- Non Small Cell Lung CancerNon-small Cell Lung CancerNon-small Cell Carcinoma
- Interventions
- First Posted Date
- 2021-03-10
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 30
- Registration Number
- NCT04791839
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies
- Conditions
- MelanomaAdvanced Solid TumorEsophageal CancerNon Small Cell Lung Cancer (NSCLC)Multiple MyelomaCervical CancerLymphoma, Non-HodgkinDiffuse Large B Cell Lymphoma (DLBCL)Gastroesophageal Junction AdenocarcinomaGastric Cancer
- Interventions
- First Posted Date
- 2021-02-26
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- Arcus Biosciences, Inc.
- Target Recruit Count
- 94
- Registration Number
- NCT04772989
- Locations
- 🇺🇸
University of Wisconsin - Madison, Madison, Wisconsin, United States
🇺🇸Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸Virginia Cancer Specialists, Fairfax, Virginia, United States
Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of GS-3583 in Participants With Advanced Solid Tumors
- Conditions
- Advanced Solid Tumors
- Interventions
- First Posted Date
- 2021-02-10
- Last Posted Date
- 2022-12-05
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 13
- Registration Number
- NCT04747470
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
🇺🇸NEXT oncology, San Antonio, Texas, United States
🇺🇸START Midwest, Grand Rapids, Michigan, United States
Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer
- Conditions
- Squamous Non Small Cell Lung CancerNon Small Cell Lung CancerNonsquamous Non Small Cell Lung CancerLung Cancer
- Interventions
- First Posted Date
- 2021-02-03
- Last Posted Date
- 2025-03-27
- Lead Sponsor
- Arcus Biosciences, Inc.
- Target Recruit Count
- 169
- Registration Number
- NCT04736173
- Locations
- 🇺🇸
Hope and Healing Cancer Service, Hinsdale, Illinois, United States
🇬🇷University General Hospital "Attikon", Chaidari, Greece
🇭🇰Humanity and Health Clinical Trial Centre, Hong Kong, Hong Kong
An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer.
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- Drug: m-FOLFOX-6 regimen
- First Posted Date
- 2020-12-09
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- Arcus Biosciences, Inc.
- Target Recruit Count
- 227
- Registration Number
- NCT04660812
- Locations
- 🇫🇷
Clinique Sainte Anne, Strasbourg, France
🇮🇹Ircc Istituto Per La Ricerca E La Cura Del Cancro Di Candiolo Oncologia Medica, Candiolo, Italy
🇮🇹IRCCS - Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis, Castellana Grotte, Italy
AB154 Combined With AB122 for Recurrent Glioblastoma
- Conditions
- Glioblastoma
- Interventions
- First Posted Date
- 2020-12-07
- Last Posted Date
- 2025-04-04
- Lead Sponsor
- Yale University
- Target Recruit Count
- 46
- Registration Number
- NCT04656535
- Locations
- 🇺🇸
University of California San Francisco, San Francisco, California, United States
🇺🇸Yale University, New Haven, Connecticut, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.